報價延遲最少15分鐘:2024/05/16 17:30 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6675 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.26/0.02
|
|
企業價值
113.04M
|
| 資產負債 |
|
每股賬面淨值
0.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 17:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for thetreatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |